Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00165035 · ClinicalTrials.gov registry record · Phase 3
Cobalt Chromium Stent With Antiproliferative for Restenosis II Trial (COSTAR II)
A Phase 3 study, sponsored by Cordis US.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,701
- Enrollment target
NCT00165035: Completed Phase 3 study, sponsored by Cordis US.
NCT00165035 is a Phase 3 study that has completed, run by Cordis US. The registered enrollment target is 1,701 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (120% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00165035, a Phase 3 study, has completed, sponsored by Cordis US.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,701 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and effectiveness of the investigational stent CoStar™ Paclitaxel-Eluting Coronary Stent- a reservoir based DES system in comparison to a surface coated DES stent (TAXUS™ Express2™ Paclitaxel-Eluting Coronary Stent) in the treatment of single-vessel (one blood vessel) and multi-vessel (two or three blood vessels) coronary artery disease.
Interventions
- DEVICE CoStar Paclitaxel Drug Eluting Coronary Stent System
- DEVICE TAXUS™ Express2™ Paclitaxel-Eluting Coronary Stent
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,701 participants |
| Start Date | 2005-05 |
| Est. Completion | 2011-07 |
| Phase | Phase 3 |
What the finished NCT00165035 record still lists
NCT00165035 is an interventional study that assigns participants to a tested intervention. Its 1,701 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (120% higher).
The record links to 0 conditions, and to 2 interventions - of which CoStar Paclitaxel Drug Eluting Coronary Stent System is the first listed.
NCT00165035 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00165035 about?
NCT00165035 is a clinical study titled "Cobalt Chromium Stent With Antiproliferative for Restenosis II Trial (COSTAR II)". The purpose of this study is to evaluate the safety and effectiveness of the investigational stent CoStar™ Paclitaxel-Eluting Coronary Stent- a reservoir based DES system in comparison to a surface coated DES stent (TAXUS™ Express2™ Paclitaxel-Eluting Coronary Stent) in the treatment of single-vesse...
What is the current status of trial NCT00165035?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,701 participants. The study started on 2005-05. Estimated completion is 2011-07.
What interventions are being tested in trial NCT00165035?
The interventions under investigation include: CoStar Paclitaxel Drug Eluting Coronary Stent System (DEVICE), TAXUS™ Express2™ Paclitaxel-Eluting Coronary Stent (DEVICE).
Who is sponsoring clinical trial NCT00165035?
This trial is sponsored by Cordis US, which has 19 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00165035's enrollment target sits among peer trials
1,701 132nd of 2000 higher than 1,869 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04321200 · 1,700 participants
PANDA Gym: Automated Assessment of Neurodevelopment in Infants at Risk for Motor Disability
- NCT06238622 · 1,700 participants · Phase 3
A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast
- NCT07284901 · 1,700 participants · Phase 3
Efficacy and Safety of KAI-9531 Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes
- NCT07304531 · 1,705 participants
First To Know Pregnancy Test - Clinical Evaluation Protocol
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia